Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report.
Birgitte TholinMarit Teigen HaugePål AukrustLutz FehrleTor Henrik TvedtPublished in: Journal of medical case reports (2020)
COVID-19 may induce a hyperinflammatory clinical picture and in some cases develop into hemophagocytic lymphohistiocytosis. In our patient's case, therapeutic interleukin-6 blockade abrogated signs of hyperinflammation but did not seem to improve pulmonary function. Measurement of ferritin and C-reactive protein, as well as quantification of interleukin-6 on indication, should be performed in patients with severe COVID-19. Specific treatment in such patients must also be contemplated, preferably in randomized controlled trials.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- newly diagnosed
- randomized controlled trial
- case report
- ejection fraction
- rheumatoid arthritis
- respiratory syndrome coronavirus
- chronic kidney disease
- peritoneal dialysis
- clinical trial
- juvenile idiopathic arthritis
- replacement therapy
- combination therapy
- iron deficiency